Nav: Home

How human genetic data is helping dogs fight cancer

June 25, 2019

Some of what we learn through the compassionate treatment of dogs with cancer goes on to help human patients. Now a study by researchers at University of Colorado Cancer Center and Colorado State University Flint Animal Cancer Center returns the favor: We know so many of the genetic changes that cause human cancer - the current study, recently published in the journal Molecular Cancer Therapeutics, sequences 33 canine cancer cell lines to identify "human" genetic changes could be driving these canine cancers, possibly helping veterinary oncologists use more human medicines to cure cancer in dogs.

"We're taking what we know from human cancers and applying it in canine cancers to help move the canine cancer treatment forward faster," says Dawn L. Duval, PhD, investigator at CU Cancer Center and assistant professor in the CSU College of Veterinary Medicine and Biomedical Sciences.

The study used whole-exome sequencing, which identifies the structure of a cell's protein-producing genes (excluding genes that sit silently in the genome). Humans have about 23,000 genes with many genetic variations naturally found in each cell. The vast majority of these variations are meaningless; a very few cause cancer. In the current study, the group was able to identify 61 genetic variants in these canine cancer cell lines that match known drivers of human cancer.

"Our goal was to start to connect the dots from genetic variations we were seeing on an analytical, screening level to variants that were truly driving cancer and could be explored as druggable targets," Duval says.

The study went beyond simply identifying these targets.

"We did all this variant finding and and at that point it was all very theoretical. Then we used a molecularly targeted drug - a MEK inhibitor - across the whole panel. Sure enough, what we saw was that canine cell lines with mutations in MAPK pathway genes, matching those known to cause human cancers, were sensitive to the same drugs that we would use with humans," Duval says.

Interestingly, the study could bring benefit full circle. After identifying these human oncogenes in canine cancer cells, the group placed the genes they found into 10 functional categories - "Categories of genes that control things like proliferation, cell cycle, DNA repair, etc.," Duval says. Then, in each of these categories, the group placed a "heat map" of genetic variants not yet known to cause cancer, but suspicious due to their prevalence in these cancer cell lines.

"The goal was to say, for example, here's a BRAF mutation - we know this is a cancer driver and here are all these other genes that had alterations that were grouped with BRAF. So here are genes to look at in the future. It's a way to discover new cancer drivers in dogs, which could potentially be new drivers in humans as well," Duval says.

By determining which canine cancers are most like human cancers, the group may also be able to transfer lessons learned while treating these human-like canine cancers back to the treatment of human patients.

"This would allow us to run drug trials in dogs that can be used to optimize therapies for both species," Duval says.

The goal now is to sequence more tumors from dogs and to develop additional cell lines to expand the panel. Eventually, the project could help to discover which human drugs work against cancer in dogs and which dog cancers closely resemble human cancers in both the driving mutations and drug responses. And just as the genes found to cause cancer in humans may also be targets for cancer in dogs, this process that leads to the discovery of cancer-causing genes in dogs could lead to new targets for anti-cancer drugs in humans.
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...